FIRST QUARTER 2018

EARNINGS CONFERENCE CALL

APRIL 30, 2018
Allergan Cautionary Statements
Forward Looking Statements
This communication includes statements that refer to estimated or anticipated future events and are forward looking statements. We have based our forward looking statements on management’s beliefs and assumptions based on
information available to our management at the time these statements are made. Such forward looking statements reflect our current perspective of our business, future performance, existing trends and information as of the date of
this filing. These include, but are not limited to, our beliefs about future revenue and expense levels and growth rates, prospects related to our strategic initiatives and business strategies, including the integration of, and synergies
associated with, strategic acquisitions, express or implied assumptions about government regulatory action or inaction, anticipated product approvals and launches, business initiatives and product development activities, assessments
related to clinical trial results, product performance and competitive environment, and anticipated financial performance. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,”
“plan,” “intend,” “could,” “would,” “should,” “estimate,” “continue,” or “pursue,” or the negative or other variations thereof or comparable terminology, are intended to identify forward looking statements. The statements are not
guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. We caution the reader that these statements are based on certain assumptions, risks and uncertainties, many of
which are beyond our control. In addition, certain important factors may affect our actual operating results and could cause such results to differ materially from those expressed or implied by forward looking statements. These
factors include, among others the inherent uncertainty associated with financial projections; the anticipated size of the markets and continued demand for Allergan’s existing products; Allergan’s ability to successfully develop and
commercialize new products; Allergan’s ability to conform to regulatory standards and receive requisite regulatory approvals; availability of raw materials and other key ingredients; uncertainty and costs of legal actions and
government investigations; fluctuations in Allergan’s operating results and financial condition, particularly given our manufacturing and sales of branded products; the impact of uncertainty around of timing of generic entry related to
key products, including Restasis ®, on our financial results; risks associated with acquisitions, mergers and joint ventures, such as difficulties integrating businesses, uncertainty associated with financial projections, projected cost
reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; expectations regarding contingent payments, including regarding litigation and related liabilities, purchase price adjustment or
transaction consideration payments; the results of the ongoing business following the completion of the divestiture of Allergan’s generics business to Teva; the adverse impact of substantial debt and other financial obligations on the
ability to fulfill and/or refinance debt obligations; risks associated with relationships with employees, vendors or key customers as a result of acquisitions of businesses, technologies or products; our compliance with federal and state
healthcare laws, including laws related to fraud, abuse, privacy security and others; generic product competition with our branded products; uncertainty associated with the development of commercially successful branded
pharmaceutical products; costs and efforts to defend or enforce technology rights, patents or other intellectual property; expiration of patents on our branded products and the potential for increased competition from generic
manufacturers; competition between branded and generic products; Allergan’s ability to obtain and afford third-party licenses and proprietary technology we need; Allergan’s potential infringement of others’ proprietary rights; our
dependency on third-party service providers and third-party manufacturers and suppliers that in some cases may be the only source of finished products or raw materials that we need; Allergan’s competition with certain of our
significant customers; the impact of our returns, allowance and chargeback policies on our future revenue; successful compliance with governmental regulations applicable to Allergan’s and Allergan’s respective third party providers’
facilities, products and/or businesses; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; Allergan’s vulnerability to and ability to defend against product
liability claims and obtain sufficient or any product liability insurance; Allergan’s ability to retain qualified employees and key personnel; the effect of intangible assets and resulting impairment testing and impairment charges on our
financial condition; Allergan’s ability to obtain additional debt or raise additional equity on terms that are favorable to Allergan; difficulties or delays in manufacturing; our ability to manage environmental liabilities; global economic
conditions; Allergan’s ability to continue foreign operations in countries that have deteriorating political or diplomatic relationships with the United States; Allergan’s ability to continue to maintain global operations and the exposure to
the risks and challenges associated with conducting business internationally; risks associated with tax liabilities, or changes in U.S. federal or international tax laws to which we are subject, including the risk that the Internal Revenue
Service disagrees that Allergan is a foreign corporation for U.S. federal tax purposes; risks of fluctuations in foreign currency exchange rates; risks associated with cyber-security and vulnerability of our information and employee,
customer and business information that Allergan stores digitally; Allergan’s ability to maintain internal control over financial reporting; changes in the laws and regulations, affecting among other things, availability, pricing and
reimbursement of pharmaceutical products; the highly competitive nature of the pharmaceutical industry; Allergan’s ability to successfully navigate consolidation of our distribution network and concentration of our customer base; the
difficulty of predicting the timing or outcome of pending or future litigation or government investigations; developments regarding products once they have reached the market; risks related to Allergan’s incorporation in Ireland, such
as changes in Irish law and such other risks and other uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the
year ended December 31, 2017, and from time to time in Allergan’s other investor communications. Except as expressly required by law, Allergan disclaims any intent or obligation to update or revise these forward-looking
statements.

Non‐GAAP Financial Measures

This document contains non‐GAAP financial measures. The Appendix hereto presents reconciliations of certain non‐GAAP financial measures to the most directly comparable GAAP measures. The non‐GAAP measures include non-GAAP
performance net income, non-GAAP performance net income per share, adjusted EBITDA, adjusted operating income and other non-GAAP financial statement line items.

The Company believes that its non-GAAP measures provide useful information to investors because these are the financial measures used by our management team to evaluate our operating performance, make day to day operating
decisions, prepare internal forecasts, communicate external forward looking guidance to investors, compensate management and allocate the Company’s resources. We believe this presentation also increases comparability of period
to period results.

The Company’s determination of significant charges or credits may not be comparable to similar measures used by other companies and may vary from period to period. The Company uses both GAAP financial measures and the
disclosed non-GAAP adjusted financial measures internally. These non-GAAP adjusted financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

2
Agenda
Q1 2018 Highlights
1 Brent Saunders, Chairman & CEO

Commercial Highlights
2 Bill Meury, Chief Commercial Officer

R&D Update
3 David Nicholson, Chief R&D Officer

Q1 2018 Financial Results

4 Matt Walsh, Chief Financial Officer

5 Q&A

3
BRENT
SAUNDERS
CHAIRMAN & CEO
Q1 2018: Solid Execution on All Fronts

Revenue and Performance Net Continued to Advance the

Income per Share growth Key Pipeline Programs
• Net revenues = $3.67B • Ubrogepant 2nd Phase 3 data
Growth positive results
+3% growth YoY including LOEs impact Pipeline
• Cariprazine Bipolar Depression
• Performance net income per share Phase 3 study RGH-MD-53
of $3.74 positive topline results
+12% growth YoY SOLID
EXECUTION
Commitment to Strong Margins Capital Deployment
• Restructuring initiatives in place • Net Debt paydown by $3.6B
Margins Capital
Gross Debt/EBITDA at 3.2x
• On track to achieve $400M operating Allocation
expenses savings • Completed $2B Share repurchase
• Adjusted Operating Margin of 47.9%

Performance net income per share, performance net income per share growth, adjusted operating margin and EBITDA refer to Non-GAAP metrics.
Please refer to the GAAP to non-GAAP tables in appendix for a reconciliation of our non-GAAP results. 5
Q1 2018 Revenue Performance Drivers

$3,213M $459M $3,672M

+13% YoY growth Brands Facing
(+6% ex. M&A & ex. Fx)
LOE Risk3 Total Q1 2018
Net Revenues
• 13% of Q1 2018 Revenues
Promoted Brands & 3% YoY Revenue Growth
Brands With Ongoing • Minastrin (1% ex-Fx)
Exclusivity1 • Aczone
• Estrace
$2,757M • Namenda XR
87%
of Q1 2018
Revenues

Other Product
Revenues2
$456M

1. Includes new product launches. 2. Includes established brands, all other product revenues and other revenues. 3. Includes brands with patent expiration and/or risk of generic
competition in 2017-2020.
Refer to Table 13 in the appendix.
6
M&A refers to the acquisitions of LifeCell and Zeltiq
BILL
MEURY
CHIEF COMMERCIAL OFFICER
Double Digit Growth from Key Promoted Products
Offset by Decline From Products Losing Exclusivity

($M) 10 6
7 25

152 49
-1%
-2% -5%
57

-60%
89 -15% 67
3,672
2.8%1
17 31 -51%
15 82
61
12
10 58%
9 -91%
3,573 6

14% 15% 12% -67%

13% 11% 8% 7%

Q1’17
Q1’18
Rev
Rev

1. 1.1% growth excluding FX. 2. Includes Viberzi, Namzaric, Kybella, Xen, True Tear, Rhofade, Viibryd/Fetzima, Carafate/Sulcrate and all other products
8
Q1 2018 Results Continue to Show Strong
Sustainable Growth Across Key Therapeutic Areas
GROWTH FUELED ACROSS STABLE GROWTH
3 PILLARS EXCLUDING RESTASIS

FACIAL Botox Cx (+10%) and Juvederm collection Glaucoma drops International growth
GLAUCOMA
AESTHETICS (+7%) continued to show strong global growth (+3%) offset by decline in US Lumigan
-1% and Alphagan
o US growth impacted in the quarter due to growth Y/Y
7% change in timing of physicians program
growth Y/Y

BODY Business is accelerating with 3,400 total Ozurdex continues to grow at double digit
accounts RETINA
CONTOURING rates in both US and International
Proforma US growth of 31% vs P/Y offset by 13% Pipeline focus to shift retina paradigm
9%
International decline due to ongoing growth Y/Y treatment with Abicipar
proforma
restructuring of in-market distribution model
growth Y/Y

PLASTICS & Alloderm strong growth (+29% proforma) DRY EYE Restasis (-15%); Eye Drops (-2%)
REGENERATIVE
MEDICINE Breast implants growth of 11% driven by -12% US Restasis demand growth of 4% offset by
momentum from new premium Inspira implants growth Y/Y trade buying patterns and lower net pricing
15%
proforma • MDPF share of total volume at ~25%
growth Y/Y
All growth rates exclude Fx
Glaucoma group includes: Lumigan/Ganfort, Alphagan/Combigan, and Xen. Glaucoma drops excludes Xen.
Retina group includes: Ozurdex. Dry Eye group includes: Restasis and eye drops
9
Source: MDPF share: IMS RX AUDIT WEEKLY week ending 03/30
Q1 2018 Results Continue to Show Strong
Sustainable Growth Across Key Therapeutic Areas
GROWTH ANCHORED BY
BLOCKBUSTER FRANCHISE
VRAYLAR AND BOTOX TX

1,700
Vraylar NTBRx DTC Active • Flagship product of GI franchise on its way to $1B
+43% Constipation
1,500 • Strong demand growth continued in Q1’18 (+16%)
1,300 8%
58% 1,100 growth Y/Y • New DTC campaign will continue to drive OTC
growth Y/Y 900 conversion
700
500
300 • 40K lipase strength major growth driver
in gastroenterology
• Additional promotional effort in 2018 to
14% target high enzyme writers
Botox Tx revenuesSales
across 9 indications growth Y/Y

Therapeutic
15%
15% OAB
Other
9% 40% • Demand stable
growth Y/Y Migraine
11% • Right sized investment for profitability
Still highly Cervical
underpenetrated Dystonia Spasticity 14% • Primary Care is main growth driver
25% growth Y/Y (>50% of New Prescribers)

All growth rates exclude Fx 10

Source: Vraylar: IMS
Sustained International Revenue Growth
Q1 GROWTH OF 17% (9% EX-FX) POWERED BY MEDICAL AESTHETICS AND STRONG
GROWTH FROM APAC AND LACAN
✓ International Revenues anchored by Medical
Aesthetics, Eye Care and Botox Tx
• Medical Aesthetics growth driven by Botox Cx (+15%) and
Juvederm Collection (+11%)

Europe China+56% • Ozurdex (+13%) continues to drive growth in Eye Care

+9%

Q1 2018 International Revenue Break-down

APAC/
MEA
LACAN Iberia+16% Other
+7%
+14% 8%
CoolSculpting/
11% 16% RM/Plastic
Botox
Tx Medical
Aesthetics 41% Juvederm
Brazil +29% Collection
Eye Care
41%
40% Botox Cx
41%

Growth rates reflect Q1 2018 growth versus prior year excluding FX impact
LACAN: Latin America and Canada. APAC / MEA: Asia Pacific / Middle East and Africa 11
DAVID
NICHOLSON
CHIEF R&D OFFICER
 Cariprazine: sNDA Submission on Track for 2H2018
RGH-MD-53 Study
Met primary efficacy objective and well
tolerated. MADRS total score change from
baseline to week 6 was statistically significant
for 1.5 mg dose.
(*) Week 6 (primary endpoint), Adjusted P-values: Car 3mg vs Pl
= 0.1051; Car 1.5mg vs Pl = 0.0417. (†) Week 2, Non-adjusted P-
values: Car 3mg vs Pl = 0.0115; Car 1.5mg vs Pl = 0.0767. (‡)
Week 4, Non-adjusted P-values: Car 3mg vs Pl = 0.0990; Car 1.5mg
vs Pl = 0.0416.
RGH-MD-54 Study
Met primary efficacy objective and well
tolerated. MADRS total score change from
baseline to week 6 was statistically significant
for both 1.5 mg and 3 mg doses.
(*) Week 6 (primary endpoint), Adjusted P-values: Car 3mg vs Pl
= 0.0103; Car 1.5mg vs Pl = 0.0331. (†) Week 2, Non-adjusted P-
values: Car 3mg vs Pl = 0.0016; Car 1.5mg vs Pl =0.0174. (‡) Week
4, Non-adjusted P-values: Car 3mg vs Pl = 0.0040; Car 1.5mg vs Pl
=0.0893.
RGH-MD-56 Study
Met primary efficacy objective. MADRS total
score change from baseline to week 6 was
statistically significant for 1.5mg dose.
(*) Week 6 (primary endpoint), Adjusted P-values: Car 3mg vs Pl =
0.1122; Car 1.5mg vs Pl = 0.0030; Car 0.75mg vs Pl = 0.1292. (†)
Week 2, Non-adjusted P-values: Car 3mg vs Pl = 0.0045; Car 1.5mg
vs Pl = 0.0013; Car 0.75mg vs Pl = 0.0025. (‡) Week 4, Non-adjusted
P-values: Car 3mg vs Pl = 0.0005; Car 1.5mg vs Pl = 0.0006; Car
0.75mg vs Pl = 0.0020.
13
 Ubrogepant Meets Co-Primary Endpoints and Demonstrates
Increasing Efficacy Beyond 2 hours in Two Phase 3 Studies
ACHIEVE I – Phase 3 ACHIEVE II – Phase 3
Co-Primary Endpoints Met For Ubrogepant at Co-Primary Endpoints Met For Ubrogepant at
50mg and 100mg Dose1 50mg Dose1
Placebo Ubro 50mg Ubro 100mg Placebo Ubro 25mg Ubro 50mg
Endpoints Statistics Endpoints Statistics
(N=456) (N=423) (N=448) (N=456) (N=435) (N=464)
Pain Free at 2 Pain Free at 2
Co-Primary Endpoint 1: 11.8 19.2 21.2 Co-Primary Endpoint 1: Pain Hours, % 14.3 20.7 21.8
Hours, %
Pain Freedom 2 Hours After Freedom 2 Hours After Initial
Adjusted Dose Adjusted
Initial Dose - 0.0023 0.0003 - 0.0285 0.0129
p-value p-value
Co-Primary Endpoint 2: Absence of Co-Primary Endpoint 2: Absence of
27.8 38.6 37.7 MBS2, % 27.4 34.1 38.9
Absence of Most Bothersome MBS2, % Absence of Most Bothersome
Symptom2 2 Hours After Adjusted Symptom2 2 Hours After Adjusted
Initial Dose - 0.0023 0.0023 Initial Dose - 0.0711 0.0129
p-value p-value

Kaplan-Meier Plot of Time to Pain Freedom Within Kaplan-Meier Plot of Time to Pain Freedom Within
8 Hours of Initial Dose 8 Hours of Initial Dose
100 100.0
Placebo (*) (*)
80 Ubrogepant 50mg 80.0

Percent
Percent

Percent
Percent

60 Ubrogepant 100mg 60.0

40 40.0
20 20.0
0 0.0
0 0.5 1 1.5 2 3 4 6 8 0 0.5 1 1.5 2 3 4 6 8
Time After Dose (Hours) Time After Dose (Hours)
(*) P-value < 0.0001, log-rank test comparing the 3 survival curves (*) P-value < 0.0001, log-rank test comparing the 3 survival curves

Note: Modified ITT population only.

1. As compared to Placebo. 14
2. Most Bothersome Symptoms including Photophobia, Phonophobia or Nausea.
Advancing the Pipeline Beyond 6 Stars
Estimated timelines 2017 2018 2019 2020
ESMYA FDA approval
Uterine fibroids and launch

Ubrogepant Ph. III recruitment Ph. III topline results Launch

Acute migraine complete

Atogepant Ph. IIb topline results

Prophylaxis migraine

Cariprazine Positive Ph. III topline Launch

Bipolar Depression

Rapastinel Ph. III on track Ph. III short-term topline Maintenance topline
Depression results results
Abicipar Ph. III topline results Launch
AMD

Abicipar Ph. III initiation

DME

Bimatoprost SR Ph. III enrollment Launch

Glaucoma completion
Pilo/Oxy Ph. IIb enrollment Ph. III initiation
Presbyopia completion
CVC Ph. III initiated Ph. II combination
NASH CVC/LJN452

Relamorelin Ph. III initiated

Gastroparesis Ph. III topline results

Brazikumab Ongoing Ph. II Ph. III initiation

Crohn’s

Brazikumab Ph. II initiation

UC

Botox Ongoing Ph. IIb/III

Platysma/Masseter

15
MATT
WALSH
CHIEF FINANCIAL OFFICER
 Q1 2018 Strong Financial Performance on All Fronts
Solid Top Line Growth in Promoted Brands Maintaining Leading Operating Margins
Offsetting LOEs
Ex. RM &
$3,672 Coolsculpting
$3,573 YoY Rev. Growth % Actual Ex. Fx 87.3% • Gross Margin impacted by product mix
Ex. Fx 86.2%
including Alloderm & CoolSculpting
Promoted Brands w/ 47.9%
Ongoing Exclusivity
17.2% 14.9% 8.8%
45.3%
(lower GM products) and LOEs
2,353 2,757
Other Product Rev -4.9% -6.1% -6.2% • Op. Margin improvement due to cost
480 Core Business1 13.4% 11.4% 6.2% saving initiatives and operating
456 Brands facing LOE -38.0% -38.2% -38.2% expense timing
740 Q1’17 Q1’18 Q1’17 Q1’18
459 Total Revenues 2.8% 1.1% -3.2% Non-GAAP Gross Adjusted Operating
($M) Q1'17 Q1'18 Margin Margin
1. Promoted brands w/ ongoing exclusivity + Other product rev

Profit Growth Well Ahead of Revenue Growth

$ Sustainable Generation of Operating Cash Flow

12% LTM* Operating Cash Flow by end of

9% • Performance net income grew 9% each Quarter ($B)
$3.74
$1,306 due to strength of Promoted Brands $6.6
and lower operating expenses $5.9
• Strong Q1’18 OCF of $1.46B
$3.35 including positive working capital
$1,196
• Performance net income per share contribution
$3.7
grew 12% impacted by lower share
count from timing of share buybacks • Q1’18 performance supports full
$1.2* year guidance of ~$5.0B
Q1’17 Q1’18 Q1’17 Q1’18
Non-GAAP Performance Non-GAAP Performance
Q2'17 Q3'17 Q4'17 Q1'18
Net Income ($M) Net Income per Share
* LTM OCF includes taxes related to the sale of the Gx business

Non-GAAP gross margin, adjusted operating margin, Non-GAAP performance net income and Non-GAAP performance net income per share refer to Non-GAAP metrics.
Please refer to the GAAP to non-GAAP tables in appendix for a reconciliation of our non-GAAP results 17
Q1 2018 Financial Performance
$ millions, except per
share amount
Q1 2018 Q1 2017 ∆ Y/Y
(Non GAAP)*

Net Revenue 3,672.1 3,572.9 2.8%

Gross Margin % 86.2% 87.3% -1.1% Solid Revenue Growth of 3%1 versus prior year

• Growth mainly driven by the addition of Regenerative Medicine products, CoolSculpting and
R&D Expense 355.8 393.9 -9.7%
continued growth of key brands
% of Revenue 9.7% 11.0% -1.3%

S&M 784.5 843.2 -7.0% • Offset by Namenda XR, Estrace, Minastrin and Asacol HD loss of exclusivity
G&A 264.2 262.7 0.6%
Margins Remain Strong versus prior year
SG&A 1,048.7 1,105.9 -5.2%
% of Revenue 28.6% 31.0% -2.4% • Gross margin decline of 1.1% mainly attributed to negative impact from product mix, including
CoolSculpting and Alloderm
Adjusted Operating
Income
1,759.1 1,617.8 8.7% • Operating margins increase of 2.6% due to lower operating expenses
Adj Op. Margin % 47.9% 45.3% 2.6%
Net Interest Expense/Other were stable versus prior year due to savings from debt
Net Interest refinancing and debt paydown throughout 2017 and 2018 partially offset by lower “other
(239.2) (239.6) -0.2%
(Expense) /Other income” which does not include a Teva dividend in Q1 2018

Performance Net
$3.74 $3.35 11.6% Strong Cash Flow from Operations at $1.46B
Income per Share

Tax Rate 14.1% 13.2% 0.9%

Cash Flow From

1,458.3 723.3 101.6%
Ops

* Please refer to the GAAP to non-GAAP tables in the appendix for a reconciliation of our non-GAAP results
1. 1.1% excluding Fx 18
 Q1 2018 Performance by Segment
(Revenues $M)
1,482 1,579
1,346
6.5% 1,224
-9.1%
864
737 17.2%

9.0%
Ex-Fx 7.8 5.8

Q1’17 Q1’18 Q1’17 Q1’18 Q1’17 Q1’18 7

Q1’17 Q1’18
US Specialized Therapeutics US General Medicine International Corporate

Contribution 68.7% 68.5% 60.0% 63.5% 53.9% 53.9%

Margin
N/A

US Specialized Therapeutics revenue growth driven by Regenerative Medicine, CoolSculpting and growth in key brands offset by
decline in Restasis and Med Derm
• Contribution margin slightly declined due to lower margins from Regenerative Medicine and CoolSculpting

US General Medicine revenues decline attributed to impact from LOEs more than offsetting strong growth in Vraylar, Lo Loestrin
and Linzess
• Contribution margin improvement due to restructuring initiatives to right size the business given LOEs

International revenue growth driven by Facial Aesthetics, Botox Tx, Ozurdex and CoolSculpting
• Contribution margin remained stable to support strong growth

> Revenue growth and contribution margins refer to non-GAAP

19
Capitalization as of March 31 st 2018

Capitalization ($B) Q1 2018

Cash and Marketable Securities1 $2.0

Total Debt $26.6

Debt to Adjusted EBITDA 3.2x

Net Debt to Adjusted EBITDA 3.0x

• Total debt paid down by $3.6B2

• Completed $2B share buyback3

1. Includes Teva shares valued at $1.0B including value retained for a forward sale agreement on 25M Teva Shares
2. Includes $3.75B in contractual maturities in Q1 2018 plus $372M in margin loan repayments less a net $500M of revolver drawdown
3. Share buyback 99.5% complete
Adjusted EBITDA refers to non-GAAP. Please refer to the GAAP to non-GAAP tables in appendix for a reconciliation of our non-GAAP results

20
Increased and Narrowed FY 2018 Guidance
$ In millions, except FY 2018 Prior FY 2018 Updated
Assumptions
for share amounts Guidance Guidance
• Restasis generic entry between May – July 2018
Total Net Revenue $15,000 – $15,300 $15,150 – $15,350 • Estrace, Namenda XR, Aczone generic
competition ongoing; Delzicol Q2

Non-GAAP Gross Margin 85.5% – 86.0% 85.5% – 86.0% • No change

Non-GAAP SG&A ~$4,250 ~$4,250 • No change

Non-GAAP R&D Spend ~$1,500 ~$1,500 • No change

Non-GAAP Tax rate % ~14.0% ~14.0% • No change

Non-GAAP Net Interest

~$900 ~$900 • No change
Expense/Other

Non-GAAP Adjusted Diluted • Reflects topline increase and lowered share

$15.25 – $16.00 $15.65 – $16.25
Performance Net Income per Share count
• Reflects $2B share buyback completion in Q1
Non-GAAP Average Share Count ~350 Million ~345 Million
2018
• Includes all success based milestones from
Cash Flow from Operations $4,700 – $5,000 ~$5,000 existing transactions, restructuring and other
payments

2Q 2018 Guidance
Total Reported Net Revenue $3,850 – $4,000 Reflects Restasis generic entry between May – July 2018
Non-GAAP Adjusted Diluted
$4.00 - $4.20
Performance Net Income per Share

Please refer to the GAAP to non-GAAP tables in appendix for a reconciliation of our non-GAAP guidance
21
APPENDIX
Potential Cash Impact from R&D and Approval Milestones

✓ SUCCESS BASED DEVELOPMENT AND APPROVAL MILESTONES CASH FLOW POTENTIAL IMPACT

Q2 - Q4
($M) Q1 2018 FY 2019 FY 2020 FY 2021 FY 2022 Thereafter
2018
CF Operating 37 548 122 249 236 8 1,079

CF Investing - 27 137 81 158 303 2,751

CF Financing - 23 0 58 150 - 80

Total 37 598 259 388 544 311 3,910

Amounts in the table above represent payments assuming all anticipated milestones are achieved on commitments in place as of March 31, 2018, including milestones accrued as of March 31,
2018 to be funded in future periods. Amounts and timing are subject to change depending on project status.

Subsequent to March 31, 2018, Allergan acquired Elastagen for an upfront cash payment of approximately $95M which was committed as of March 31, 2018 and included in the above table.

Amounts in the table above only reflect R&D Milestone payments and Approval Milestones; Sales Milestones are not included. Such milestone payments will only be payable in the event that
the Company achieves contractually defined, success-based milestones, such as the advancement of the specified research and development programs or the receipt of regulatory approval for
the specified compounds or products.

24
Q1 2018 Cash and Marketable Securities
Includes: Includes: Includes: Includes:
Net sale of investments and other Dividends (320) Net sale of marketable securities (3,434)
Severance and integration 3,434 Teva settlement (234)
(72) Assets
payments1 Non-cash movement in
Share buybacks (1,440)
Teva settlement (466) marketable securities including
Net repayments of long-term (161)
(3,613) the impact of derivative
Payments for R&D milestones (37) indebtedness
Capital Expenditures (46) instruments2
Forward Sale of Teva Securities 372

$2,932
($5,208)
($M)
$1,458

$6,449
($3,595)

($4.0)
$2,032

12/31/17 Cash Flow from Cash Flow from Cash Flow from Change in Marketable Other comprehensive 03/31/18
Cash & Marketable Operations Investing Financing Securities income on Cash & Cash & Marketable
Securities Marketable Securities Securities

1. Includes severance payments of $51.3M which reduced accrued liabilities.

2. Movement in marketable securities include mark-to-market movements for securities held as well as the movement of value between marketable securities and other working capital components relating to
derivative transactions from the sale of Teva securities.

25
Continue to Advance the Pipeline …
2018 Achievements and Key 2019 Highlights
THERAPEUTIC AREAS APPROVALS SUBMISSIONS DEVELOPMENT MILESTONES
Voluma XC (Cannula) Brazikumab

MEDICAL
Volift-
NLF/Volbella-Lips
Sarecycline
Acne 2H
Microcell
Inspira  Volift/NLF
(China) 2H
topline 2H Psoriasis Ph2 FPD 2H

AESTHETICS/
(JPN) 1H
Botox
(US) 1H
Phoenix
Voluma Chin Tissue Shapes for  Setipiprant
Hair Growth topline 2H


CoolSculpting (US) 1H Pre-Pec Launch (US)
DERMATOLOGY Jawline
(US) 2H
CFL
(China) 2H
Microcell TE
410 (US) 1H
CE Mark
(EU) 1H
1H Voluma Nose
(China) FPD 1H

Abicipar AMD Restaysis Abicipar AMD Bimatoprost SR
Pilo/Oxy
Ph 2 Topline 1H
 Abicipar AMD
Topline 2H
Bim Ring
Ph3 Entry 1H
EYE CARE (US) 2H Dry eye (US) 2H18 Glaucoma
Bimatoprost SR Ph 3 Abicipar DME
(EU) 1H (EU) 1H19 (US) 2H
enrollment completion Ph 3 Entry 2H
2H

Brazikumab Brazikumab UC
Linzess
Crohn’s Ph3 entry 2H Ph 2 Initiation 2H
Abdominal Symptoms
GI (US) 2H
CVC + LJN452
Entry Ph 2b 1H

CNS
Ubrogepant
Acute Treatment
Migraine
Cariprazine
Bipolar Dep
Cariprazine
Bipolar Dep
Ubrogepant
Acute Treatment
Migraine
Ubrogepant
1st Ph 3 Topline 1H  Atogepant
Topline
Rapastinel
Ph 3 Short Term
(US) 2H (US) 2H (US) 2H (US) 1H Cariprazine
Bipolar Depression
TLR 1H
 Ph 2/3 trial 1H Topline Results
2H

WH,
Avastin
Biosimilar
EU 1H
 ESMYA
Uterine fibroids
2H
Biosimilar
Rituxan
(US/EU) 2H
URO, AI,
OTHER
Avycaz
HABP/VABP
 Biosimilar
Herceptin
(US/EU) 1H
US 1H
Achieved YTD  2018 2019

26
Q1 2018 Reconciliation Tables
Table 1: Allergan plc’s statement of operations for the three months ended March 31, 2018 and 2017

Table 2: Allergan plc's product revenue for significant promoted products globally, within the U.S. and international for the three months ended March 31, 2018 and
2017

Table 3: Allergan plc’s Condensed Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017

Table 4: Allergan plc’s Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017

Table 5: GAAP to Non-GAAP adjustments for the three months ended March 31, 2018 and 2017

Table 6: Reconciliation of Allergan plc's reported net (loss) from continuing operations attributable to shareholders and diluted earnings per share to non-GAAP
performance net income and non-GAAP performance net income per share for the three months ended March 31, 2018 and 2017

Table 7: Reconciliation of Allergan plc's reported net (loss) from continuing operations attributable to shareholders for the three months ended March 31, 2018 and
2017 to adjusted EBITDA and adjusted operating income

Table 8: Allergan plc's segment contribution reconciled to the non-GAAP contribution for the same financial statement line items for the three months ended
March 31, 2018 and 2017

Table 9: Allergan plc's product revenue for significant promoted products and segment contribution within the US Specialized Therapeutics segment for the three
months ended March 31, 2018 and 2017

Table 10: Allergan plc's product revenue for significant promoted products and segment contribution within the US General Medicine segment for the three months ended
March 31, 2018 and 2017

Table 11: Allergan plc's product revenue for significant promoted products and segment contribution within the International segment for the three months ended March
31, 2018 and 2017

Table 12: Reconciliation of anticipated GAAP loss from continuing operations to non-GAAP performance net income attributable to shareholders for the three months
ending June 30, 2018 and twelve months ending December 31, 2018

Table 13: Three months ended March 31, 2018 and 2017 Revenue Performance Drivers by product

27
Table 1: Allergan plc’s statement of operations for the three months ended March 31, 2018 and
2017 ALLERGAN PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited; in millions, except per share amounts)

Three Months Ended

March 31,
2018 2017
Net revenues $ 3,672.1 $ 3,572.9

Operating expenses:
Cost of sales (excludes amortization and impairment of
acquired intangibles including product rights) 522.8 450.4
Research and development 474.7 759.9
Selling, general and administrative 1,095.9 1,185.2
Amortization 1,697.6 1,736.0
In-process research and development impairments 522.0 340.0
Asset sales and impairments, net 13.1 7.4
Total operating expenses 4,326.1 4,478.9
Operating (loss) (654.0) (906.0)

Non-operating income (expense):

Interest income 17.3 25.3
Interest (expense) (250.6) (289.7)
Other income (expense), net (78.8) (1,922.8)
Total other income (expense), net (312.1) (2,187.2)
(Loss) before income taxes and noncontrolling interest (966.1) (3,093.2)
(Benefit) for income taxes (682.2) (532.1)
(Loss) from continuing operations, net of tax (283.9) (2,561.1)
(Loss) from discontinued operations, net of tax - (3.1)
Net (loss) (283.9) (2,564.2)
(Income) attributable to noncontrolling interest (2.2) (1.0)
Net (loss) attributable to shareholders (286.1) (2,565.2)
Dividends on preferred shares 46.4 69.6
Net (loss) attributable to ordinary shareholders $ (332.5) $ (2,634.8)

(Loss) per share attributable to ordinary shareholders - basic:

Continuing operations $ (0.99) $ (7.85)

Discontinued operations - (0.01)
Net (loss) per share - basic $ (0.99) $ (7.86)
(Loss) per share attributable to ordinary shareholders - diluted:

Continuing operations $ (0.99) $ (7.85)

Discontinued operations - (0.01)
Net (loss) per share - diluted $ (0.99) $ (7.86)

Dividends per ordinary share $ 0.72 $ 0.70

Weighted average shares outstanding:

Basic 334.6 335.1 28
Diluted 334.6 335.1
Table 2: Allergan plc's product revenue for significant promoted products globally, within the U.S.
and international for the three months ended March 31, 2018 and 2017
AL L E RG AN P L C
NE T RE V E NUE S T O P G L O BAL P RO DUCT S
( Un au d ited ; in m illion s)

Thre e Months Ende d Ma rc h 3 1, 2 0 18 Thre e Months Ende d Ma rc h 3 1, 2 0 17 Move me nt

US S pe c ia lize d US G e ne ra l US S pe c ia lize d US G e ne ra l Tota l Cha nge
The ra pe utic s Me dic ine Inte rna tiona l Corpora te Tota l The ra pe utic s Me dic ine Inte rna tiona l Corpora te Tota l Tota l Cha nge P e rc e nta ge

Botox® $ 572.5 $ - $ 244.8 $ - $ 817.3 $ 509.4 $ - $ 204.6 $ - $ 714.0 $ 103.3 14.5%

Re s ta s is ® 255.8 - 18.3 - 274.1 308.8 - 13.9 - 322.7 (48.6) (15.1)%

J uve de rm Colle c tion 122.8 - 146.1 - 268.9 119.8 - 122.2 - 242.0 26.9 11.1%

Lumiga n®/Ga nfort® 66.8 - 100.4 - 167.2 74.3 - 85.9 - 160.2 7.0 4.4%

Linze s s ®/Cons te lla ® - 159.3 5.6 - 164.9 - 147.6 4.9 - 152.5 12.4 8.1%

Bys tolic ® /Byva ls on® - 132.8 0.5 - 133.3 - 139.8 0.6 - 140.4 (7.1) (5.1)%

Alpha ga n®/Combiga n® 84.2 - 44.2 - 128.4 86.4 - 42.3 - 128.7 (0.3) (0.2)%

Eye Drops 46.2 - 68.8 - 115.0 47.8 - 65.3 - 113.1 1.9 1.7%

Lo Loe s trin® - 114.6 - - 114.6 - 99.8 - - 99.8 14.8 14.8%

Bre a s t Impla nts 60.7 - 44.1 - 104.8 54.3 - 37.6 - 91.9 12.9 14.0%

Allode rm® 99.5 - 2.2 - 101.7 54.1 - 1.2 - 55.3 46.4 83.9%

Ozurde x ® 25.5 - 64.4 - 89.9 22.5 - 51.1 - 73.6 16.3 22.1%

Vra yla r® - 84.4 - - 84.4 - 53.6 - - 53.6 30.8 57.5%

Viibryd®/Fe tzima ® - 71.7 1.5 - 73.2 - 72.5 0.4 - 72.9 0.3 0.4%

Cools c ulpting Cons uma ble s 53.4 - 8.1 - 61.5 - - - - - 61.5 n.a .

Ca ra fa te ® /S ulc ra te ® - 56.0 0.7 - 56.7 - 58.7 0.7 - 59.4 (2.7) (4.5)%

Ze npe p® - 52.9 - - 52.9 - 46.5 - - 46.5 6.4 13.8%

As a c ol®/De lzic ol® - 38.2 11.7 - 49.9 - 57.6 12.1 - 69.7 (19.8) (28.4)%

Armour Thyroid - 48.2 - - 48.2 - 37.3 - - 37.3 10.9 29.2%

Ca na s a ®/S a lofa lk® - 38.6 4.2 - 42.8 - 38.3 4.4 - 42.7 0.1 0.2%

Na me nda XR® - 40.5 - - 40.5 - 122.0 - - 122.0 (81.5) (66.8)%

Cools c ulpting S ys te ms & Add On Applic a tors 33.7 - 1.1 - 34.8 - - - - - 34.8 n.a .

Vibe rzi® - 35.9 0.1 - 36.0 - 31.5 - - 31.5 4.5 14.3%

Na mza ric ® - 33.4 - - 33.4 - 23.6 - - 23.6 9.8 41.5%

S a phris ® - 32.7 - - 32.7 - 37.3 - - 37.3 (4.6) (12.3)%

Te fla ro® - 32.2 - - 32.2 - 30.6 - - 30.6 1.6 5.2%

Ra pa flo® 22.8 - 1.2 - 24.0 25.9 - 2.0 - 27.9 (3.9) (14.0)%

Avyc a z® - 21.8 - - 21.8 - 11.3 - - 11.3 10.5 92.9%

S a ve lla ® - 19.9 - - 19.9 - 24.3 - - 24.3 (4.4) (18.1)%

S kinMe dic a ® 18.1 - 1.6 - 19.7 28.0 - - - 28.0 (8.3) (29.6)%

La tis s e ® 13.8 - 2.2 - 16.0 13.6 - 1.9 - 15.5 0.5 3.2%

Ac zone ® 16.0 - 0.1 - 16.1 40.6 - - - 40.6 (24.5) (60.3)%

Le xa pro® - 14.7 - - 14.7 - 13.4 - - 13.4 1.3 9.7%

Da lva nc e ® - 11.9 - - 11.9 - 9.6 - - 9.6 2.3 24.0%

Kybe lla ® /Be lkyra ® 8.2 - 1.4 - 9.6 15.1 - 1.5 - 16.6 (7.0) (42.2)%

Ta zora c ® 9.4 - 0.2 - 9.6 23.4 - 0.2 - 23.6 (14.0) (59.3)%

Lile tta ® - 8.1 - - 8.1 - 7.2 - - 7.2 0.9 12.5%

Es tra c e ® Cre a m - 6.4 - - 6.4 - 73.4 - - 73.4 (67.0) (91.3)%

Mina s trin® 24 - 5.2 - - 5.2 - 41.1 - - 41.1 (35.9) (87.3)%

Ena ble x® - 0.8 - - 0.8 - 0.9 - - 0.9 (0.1) (11.1)%

Na me nda ® IR - 0.1 - - 0.1 - 0.1 - - 0.1 - 0.0%

Othe r P roduc ts Re ve nue s 69.2 163.4 90.5 5.8 328.9 58.0 167.8 84.5 7.8 318.1 10.8 3.4%

29
To ta l Ne t Re ve n u e s $ 1, 5 7 8 . 6 $ 1, 2 2 3 . 7 $ 8 6 4 .0 $ 5 .8 3 ,6 7 2 .1 $ 1, 4 8 2 . 0 $ 1, 3 4 5 . 8 $ 7 3 7 .3 $ 7 .8 3 ,5 7 2 .9 $ 9 9 .2 2 .8 %
Table 3: Allergan plc’s Condensed Consolidated Balance Sheets as of March 31, 2018 and
December 31, 2017

ALLERGAN PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited; in millions)
March 31, December 31,
2018 2017
Assets
Cash and cash equivalents $ 994.8 $ 1,817.2
Marketable securities 1,037.4 4,632.1
Accounts receivable, net 2,639.2 2,899.0
Inventories 948.4 904.5
Prepaid expenses and other current assets 773.5 1,123.9
Assets held for sale 71.8 81.6
Property, plant and equipment, net 1,769.5 1,785.4
Investments and other assets 1,160.7 587.0
Product rights and other intangibles 52,566.5 54,648.3
Goodwill 50,059.5 49,862.9
Total assets $ 112,021.3 $ 118,341.9

Liabilities & Equity

Current liabilities $ 5,189.8 $ 5,616.3
Current and long-term debt and capital leases 26,562.6 30,075.3
Deferred income taxes and other liabilities 7,922.9 8,813.2
Total equity 72,346.0 73,837.1
Total liabilities and equity $ 112,021.3 $ 118,341.9

30
Table 4: Allergan plc’s Consolidated Statements of Cash Flows for the three months ended March
31, 2018 and 2017 ALLERGAN PLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; in millions)
Three Months Ended March 31,
2018 2017
Cash Flows From Operating Activities:
Net (loss) $ (283.9) $ (2,564.2)
Reconciliation to net cash provided by operating activities:
Depreciation 56.1 41.6
Amortization 1,697.6 1,736.0
Provision for inventory reserve
14.2 23.9
Share-based compensation
72.5 62.7
Deferred income tax benefit
(1,026.4) (712.8)
In-process research and development impairments 522.0 340.0
Loss on asset sales and impairments, net
13.1 7.4
Net income impact of determining that the loss on investment of Teva securities is other-than-temporary - 1,978.0
Loss on Teva securities
77.7 -
Amortization of inventory step up
- 27.9
Amortization of deferred financing costs
6.3 6.7
Contingent consideration adjustments,
including accretion
5.3 30.7
Other, net
6.5 (18.8)
Changes in assets and liabilities (net of effects
of acquisitions):

Decrease / (increase) in accounts receivable, net 259.1 53.2

Decrease / (increase) in inventories (52.7) (50.5)
Decrease / (increase) in prepaid expenses
and other current assets (0.6) 2.5
Increase / (decrease) in accounts payable
and accrued expenses
(231.6) (363.7)
Increase / (decrease) in income and other
taxes payable
336.6 123.8
Increase / (decrease) in other assets and liabilities (13.5) (1.1)
Net cash provided by operating activities
1,458.3 723.3
Cash Flows From Investing Activities:
Additions to property, plant and equipment (46.4) (33.2)
Additions to product rights and other intangibles - (346.3)
Additions to investments (1,455.9) (6,387.9)
Proceeds from sale of investments and other assets 4,889.5 9,655.3
Payments to settle Teva related matters (466.0) -
Proceeds from sales of property, plant and equipment 11.1 0.7
Acquisitions of businesses, net of cash acquired - (2,874.4)
Net cash provided by investing activities 2,932.3 14.2
Cash Flows From Financing Activities:
Proceeds from borrowings on long-term indebtedness, including credit facility 709.0 -
Proceeds from Forward Sale of Teva securities 372.3 -
Payments on debt, including capital lease obligations (4,322.1) (1,015.9)
Proceeds from stock plans 35.5 52.6
Other financing, including contingent consideration (9.3) (76.3)
Payments to settle Teva related matters (234.0) -
Repurchase of ordinary shares (1,439.6) (29.5)
Dividends (319.5) (305.8)
Net cash (used in) financing activities
(5,207.7) (1,374.9)
Effect of currency exchange rate changes on cash
and cash equivalents
(5.3) 6.3
Net (decrease) in cash and cash equivalents (822.4) (631.1)
Cash and cash equivalents at beginning of period 1,817.2 1,724.0

31
Cash and cash equivalents at end of period $ 994.8 $ 1,092.9
 Table 5: GAAP to Non-GAAP adjustments for the three months ended March 31, 2018 and 2017

ALLERGAN PLC
GAAP TO NON-GAAP ADJUSTMENTS
(Unaudited; in millions)

Three Months Ended March 31, 2018

Asset sales
and Interest Other
Net Research & Selling & General & Impairments, expense, income Income
Revenue COGS Development Marketing Administrative Amortization net net (expense) taxes
GAAP $ 3,672.1 $ 522.8 $ 474.7 $ 800.0 $ 295.9 $ 1,697.6 $ 535.1 $ (233.3) $ (78.8) $ (682.2)

Purchase accounting impact on stock-based compensation for acquired awards - (1.1) (2.8) (4.3) (1.6) - - - - -
Severance due to integration of acquired entities - - - (0.7) (0.5) - - - - -
Non-acquisition related severance and restructuring - (12.6) (0.6) (10.3) (7.3) - (13.6) - - -
Costs associated with disposed businesses - (0.5) - - (2.6) - - - - -
Integration charges of acquired businesses - - (0.2) (0.2) (10.7) - - - - -
Milestones and upfront expenses for asset acquisitions
Chase Pharmaceuticals Corporation - - (75.0) - - - - - - -
Repros Therapeutics, Inc. - - (33.2) - - - - - - -
Other - - (5.2) - - - - - - -
Accretion and fair-value adjustments to contingent consideration - (3.4) (1.9) - - - - - - -
Non-cash amortization of debt premium recognized in purchase accounting - - - - - - - (4.8) - -
Impairment of RORyt IPR&D product - - - - - - (522.0) - - -
Asset sales and impairments, other - - - - - - 0.5 - - -
Loss on Teva securities - - - - - - - - 77.7 -
Litigation settlement related charges - - - - (10.3) - - - - -
Other adjustments - - - - 1.3 (1,697.6) - - - -
Income taxes on pre-tax adjustments - - - - - - - - - 437.8
Discrete income tax events - - - - - - - - - 459.6

Non-GAAP Adjusted $ 3,672.1 $ 505.2 $ 355.8 $ 784.5 $ 264.2 $ - $ - $ (238.1) $ (1.1) $ 215.2

32
 Table 5 (cont’d): GAAP to Non-GAAP adjustments for the three months ended March 31, 2018 and
2017

ALLERGAN PLC
GAAP TO NON-GAAP ADJUSTMENTS
(Unaudited; in millions)

Three Months Ended March 31, 2017

Asset sales
and Interest Other
Net Research & General & Impairments, expense, income Income
Revenue COGS Development Selling & Marketing Administrative Amortization net net (expense) taxes
GAAP $ 3,572.9 $ 450.4 $ 759.9 $ 869.1 $ 316.1 $ 1,736.0 $ 347.4 $ (264.4) $ (1,922.8) $ (532.1)

Impact of selling through purchase accounting mark-up on acquired inventory - (27.9) - - - - - - - -

Expenditures incurred with the Pfizer transaction - (2.0) (2.4)
Purchase accounting impact on stock-based compensation for acquired awards - (1.0) (5.6)
Severance due to integration of acquired entities and other restructuring programs - (0.3) (0.6)
Costs associated with disposed businesses - -
Integration charges of acquired businesses - (0.5) (0.9)
Milestones and upfront expenses for asset acquisitions
Assembly Biosciences, Inc. - - (50.0)
Lysosomal Therapeutics, Inc. - - (145.0)
Editas Medicine Inc. - - (90.0)
Other - - (6.1)
Accretion and fair-value adjustments to contingent consideration - 35.5 (66.2)
Net income impact of determining that the loss on investment of Teva securities is other-than-temporary - -
Non-cash amortization of debt premium recognized in purchase accounting - -
Termination of agreement for SER-120 - -
Decrease in realization of certain R&D projects acquired in the Warner Chilcott acquisition - -
Settlement of Naurex, Inc. agreement - -
Litigation settlement related charges - -
Other adjustments - 1.1 0.8
Income taxes on pre-tax adjustments - -
Discrete income tax events - -
(5.6) (10.5) - - - - -
(9.4) (6.0) - - - - -
(9.7) (3.8) - - - - -
- - (8.1) - - - - -
(0.4) (27.0) - - - - -
- - - - - - -
- - - - - - -
- - - - - - -
- - - - - - -
- - - - - - -
- - - - - - 1,978.0 -
- - - - - (10.3) - -
- - - - (147.4) - - -
- - - - (200.0) - - -
- - - - - - (20.0) -
- - 1.1 - - - - -
(0.8) 0.9 (1,736.0) - - (0.1) -
- - - - - - - 686.0
- - - - - - - 27.5

Non-GAAP Adjusted $ 3,572.9 $ 455.3 $ 393.9 $ 843.2 $ 262.7 $ - $ - $ (274.7) $ 35.1 $ 181.4

The non-GAAP income tax expense is determined based on our pre-tax income, adjusted for non-GAAP items on a jurisdiction by jurisdiction basis. The non-GAAP effective tax rate in the three months ended March 31, 2018 was impacted by U.S. income taxed at rates higher than the Irish statutory rate, partially offset by income earned in jurisdictions with tax rates lower than the Irish statutory rate.

The non-GAAP effective tax rate for the three months ended March 31, 2018 excludes a net discrete tax benefit of approximately $459.6 related to the tax effects of restructuring activities, share-based compensation and other individually insignificant items.

33
Table 6: Reconciliation of Allergan plc's reported net (loss) from continuing operations
attributable to shareholders and diluted earnings per share to non-GAAP performance net income
and non-GAAP performance net income per share for the three months ended March 31, 2018 and
2017
ALLERGAN PLC
RECONCILIATION TABLE
(Unaudited; in millions except per share amounts)

Three Months Ended

March 31,
2018 2017

GAAP to Non-GAAP Performance net income calculation

GAAP (loss) from continuing operations attributable to shareholders $ (286.1) $ (2,562.1)

Adjusted for:
Amortization 1,697.6 1,736.0
Acquisition, divestiture and licensing charges 210.2 2,358.4
Accretion and fair-value adjustments to contingent consideration 5.3 30.7
Impairment/asset sales and related costs 535.1 347.4
Non-recurring losses / (gains) - -
Non-acquisition restructurings, including Global Supply Chain initiatives 30.8 -
Legal settlements 10.3 (1.1)
Income taxes on items above and other discrete income tax adjustments (897.4) (713.5)
Non-GAAP performance net income attributable to shareholders $ 1,305.8 $ 1,195.8

Diluted earnings per share

Diluted (loss) per share from continuing operations attributable to shareholders-

GAAP $ (0.86) $ (7.65)

Non-GAAP performance net income per share attributable to shareholders $ 3.74 $ 3.35

Basic weighted average ordinary shares outstanding 334.6 335.1

Effect of dilutive securities:
Dilutive shares 14.1 22.2
Diluted weighted average ordinary shares outstanding 348.7 357.3

34
Table 7: Reconciliation of Allergan plc's reported net (loss) from continuing operations
attributable to shareholders for the three months ended March 31, 2018 and 2017 to adjusted
EBITDA and adjusted operating income
ALLERGAN PLC
ADJUSTED EBITDA and ADJUSTED OPERATING INCOME, RECONCILIATION TABLE
(Unaudited; in millions)

Three Months Ended

March 31,
2018 2017

GAAP (loss) from continuing operations attributable to shareholders $ (286.1) $ (2,562.1)

Plus:
Interest expense 250.6 289.7
Interest income (17.3) (25.3)
(Benefit) for income taxes (682.2) (532.1)
Depreciation 56.1 41.6
Amortization 1,697.6 1,736.0
EBITDA $ 1,018.7 $ (1,052.2)
Adjusted for:
Acquisition, divestiture and licensing charges 197.0 2,346.7
Impairment/asset sales and related costs 535.1 347.4
Non-recurring (gain) / losses - -
Non-acquisition restructurings, including Global Supply Chain initiatives 30.8 -
Legal settlements 10.3 (1.1)
Accretion and fair-value adjustments to contingent consideration 5.3 30.7
Share-based compensation including cash settlements 72.5 62.7
Adjusted EBITDA $ 1,869.7 $ 1,734.2
Adjusted for:
Depreciation (56.1) (41.6)
Dividend income - (34.1)
Share-based compensation not related to restructuring charges and purchase
accounting impact on stock-based compensation for acquired awards
(54.5) (40.7)
Adjusted Operating Income $ 1,759.1 $ 1,617.8

35
Table 8: Allergan plc's segment contribution reconciled to the non-GAAP contribution for the same
financial statement line items for the three months ended March 31, 2018 and 2017

ALLERGAN PLC
Segment Contribution to Non-GAAP Allergan plc Contribution
(Unaudited; $ in millions)

Three Months Ended March 31, 2018 Three Months Ended March 31, 2017
US Specialized US Specialized
Therapeutics US General International Therapeutics US General International
Segment Medicine Segment Segment Corporate Total Company Segment Medicine Segment Segment Corporate Total Company
Net revenues $ 1,578.6 $ 1,223.7 $ 864.0 $ 5.8 $ 3,672.1 $ 1,482.0 $ 1,345.8 $ 737.3 $ 7.8 $ 3,572.9
Operating expenses:
Cost of sales (1) 134.2 182.6 120.9 67.5 505.2 89.2 194.5 100.3 71.3 455.3
Selling and marketing 313.2 225.5 245.7 0.1 784.5 330.4 302.5 209.5 0.8 843.2
General and administrative 50.2 38.9 31.4 143.7 264.2 44.8 40.7 29.9 147.3 262.7
Segment contribution $ 1,081.0 $ 776.7 $ 466.0 $ (205.5) $ 2,118.2 $ 1,017.6 $ 808.1 $ 397.6 $ (211.6) $ 2,011.7
Segment margin 68.5% 63.5% 53.9% n.m. 57.7% 68.7% 60.0% 53.9% n.m. 56.3%
Segment gross margin (2) 91.5% 85.1% 86.0% n.m. 86.2% 94.0% 85.5% 86.4% n.m. 87.3%

Included within our corporate function are shared costs, including above site and unallocated costs associated with running our global manufacturing facilities, corporate general and administrative expenses and corporate initiatives.
(1) Excludes amortization and impairment of acquired intangibles including product rights.

(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.

36
Table 9: Allergan plc's product revenue for significant promoted products and segment
contribution within the US Specialized Therapeutics segment for the three months ended March
31, 2018 and 2017 ALLERGAN PLC
US Specialized Therapeutics Product Revenue
(Unaudited; in millions)

Change
Three Months Ended March 31,
2018 2017 Dollars %
Total Eye Care $ 491.1 $ 553.1 $ (62.0) (11.2)%
Restasis® 255.8 308.8 (53.0) (17.2)%
Alphagan®/Combigan® 84.2 86.4 (2.2) (2.5)%
Lumigan®/Ganfort® 66.8 74.3 (7.5) (10.1)%
Ozurdex® 25.5 22.5 3.0 13.3%
Eye Drops 46.2 47.8 (1.6) (3.3)%
Other Eye Care 12.6 13.3 (0.7) (5.3)%
Total Medical Aesthetics 635.6 490.1 145.5 29.7%
Facial Aesthetics 327.7 318.7 9.0 2.8%
Botox® Cosmetics 196.7 183.8 12.9 7.0%
Juvederm Collection 122.8 119.8 3.0 2.5%
Kybella® 8.2 15.1 (6.9) (45.7)%
Plastic Surgery 60.7 54.3 6.4 11.8%
Breast Implants 60.7 54.3 6.4 11.8%
Other Plastic Surgery - - - n.a.
Regenerative Medicine 128.2 75.5 52.7 69.8%
Alloderm® 99.5 54.1 45.4 83.9%
Other Regenerative Medicine 28.7 21.4 7.3 34.1%
Body Contouring 87.1 - 87.1 n.a.
Coolsculpting® Systems & Add On Applicators 33.7 - 33.7 n.a.
Coolsculpting® Consumables 53.4 - 53.4 n.a.
Skin Care 31.9 41.6 (9.7) (23.3)%
SkinMedica® 18.1 28.0 (9.9) (35.4)%
Latisse® 13.8 13.6 0.2 1.5%
Total Medical Dermatology 54.0 86.6 (32.6) (37.6)%
Botox® Hyperhidrosis 17.3 16.8 0.5 3.0%
Aczone® 16.0 40.6 (24.6) (60.6)%
Tazorac® 9.4 23.4 (14.0) (59.8)%
Other Medical Dermatology 11.3 5.8 5.5 94.8%
Total Neuroscience & Urology 381.3 334.7 46.6 13.9%
Botox® Therapeutics 358.5 308.8 49.7 16.1%
Rapaflo® 22.8 25.9 (3.1) (12.0)%
Other Neuroscience & Urology - - - n.a.
Other Revenues 16.6 17.5 (0.9) (5.1)%
Net revenues $ 1,578.6 $ 1,482.0 $ 96.6 6.5%

Operating expenses:
Cost of sales (1) 134.2 89.2 45.0 50.4%
Selling and marketing 313.2 330.4 (17.2) (5.2)%
General and administrative 50.2 44.8 5.4 12.1%
Segment contribution $ 1,081.0 $ 1,017.6 $ 63.4 6.2%
Segment margin 68.5% 68.7% (0.2)%
(2) 91.5% 94.0% (2.5)%
Segment gross margin
(1) Excludes amortization and impairment of acquired intangibles including product rights.
37
(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.
Table 10: Allergan plc's product revenue for significant promoted products and segment
contribution within the US General Medicine segment for the three months ended March 31, 2018
and 2017 ALLERGAN PLC
US General Medicine Product Revenue
(Unaudited; in millions)

Three Months Ended March 31, Change

2018 2017 Dollars %
Total Central Nervous System (CNS) $ 262.8 $ 309.1 $ (46.3) (15.0)%
Vraylar® 84.4 53.6 30.8 57.5%
Viibryd®/Fetzima® 71.7 72.5 (0.8) (1.1)%
Namenda XR® 40.5 122.0 (81.5) (66.8)%
Namzaric® 33.4 23.6 9.8 41.5%
Saphris® 32.7 37.3 (4.6) (12.3)%
Namenda® IR 0.1 0.1 - 0.0%
Total Gastrointestinal (GI) 388.7 387.5 1.2 0.3%
Linzess® 159.3 147.6 11.7 7.9%
Carafate®/Sulcrate® 56.0 58.7 (2.7) (4.6)%
Zenpep® 52.9 46.5 6.4 13.8%
Canasa®/Salofalk® 38.6 38.3 0.3 0.8%
Asacol®/Delzicol® 38.2 57.6 (19.4) (33.7)%
Viberzi® 35.9 31.5 4.4 14.0%
Other GI 7.8 7.3 0.5 6.8%
Total Women's Health 163.3 244.7 (81.4) (33.3)%
Lo Loestrin® 114.6 99.8 14.8 14.8%
Liletta® 8.1 7.2 0.9 12.5%
Estrace® Cream 6.4 73.4 (67.0) (91.3)%
Minastrin® 24 5.2 41.1 (35.9) (87.3)%
Other Women's Health 29.0 23.2 5.8 25.0%
Total Anti-Infectives 71.6 55.7 15.9 28.5%
Teflaro® 32.2 30.6 1.6 5.2%
Avycaz® 21.8 11.3 10.5 92.9%
Dalvance® 11.9 9.6 2.3 24.0%
Other Anti-Infectives 5.7 4.2 1.5 35.7%
Diversified Brands 274.9 299.0 (24.1) (8.1)%
Bystolic® /Byvalson® 132.8 139.8 (7.0) (5.0)%
Armour Thyroid 48.2 37.3 10.9 29.2%
Savella® 19.9 24.3 (4.4) (18.1)%
Lexapro® 14.7 13.4 1.3 9.7%
Enablex® 0.8 0.9 (0.1) (11.1)%
PacPharma 4.4 3.0 1.4 46.7%
Other Diversified Brands 54.1 80.3 (26.2) (32.6)%
Other Revenues 62.4 49.8 12.6 25.3%
Net revenues $ 1,223.7 $ 1,345.8 $ (122.1) (9.1)%

Cost of sales (1) 182.6 194.5 (11.9) (6.1)%

Selling and marketing 225.5 302.5 (77.0) (25.5)%
General and administrative 38.9 40.7 (1.8) (4.4)%
Segment contribution $ 776.7 $ 808.1 $ (31.4) (3.9)%
Segment margin 63.5% 60.0% 3.5 %
(2)
Segment gross margin 85.1% 85.5% (0.4)%
(1) Excludes amortization and impairment of acquired intangibles including product rights.
38
(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.
Table 11: Allergan plc's product revenue for significant promoted products and segment
contribution within the International segment for the three months ended March 31, 2018 and
2017 ALLERGAN PLC
International Product Revenue
(Unaudited; in millions)

Three Months Ended March 31, Change

2018 2017 Dollars %
Total Eye Care $ 343.7 $ 299.5 $ 44.2 14.8%
Lumigan®/Ganfort® 100.4 85.9 14.5 16.9%
Ozurdex® 64.4 51.1 13.3 26.0%
Alphagan®/Combigan® 44.2 42.3 1.9 4.5%
Optive® 27.8 27.5 0.3 1.1%
Restasis® 18.3 13.9 4.4 31.7%
Other Eye Drops 41.0 37.8 3.2 8.5%
Other Eye Care 47.6 41.0 6.6 16.1%
Total Medical Aesthetics 358.5 288.1 70.4 24.4%
Facial Aesthetics 296.1 245.9 50.2 20.4%
Botox® Cosmetics 148.6 122.2 26.4 21.6%
Juvederm Collection 146.1 122.2 23.9 19.6%
Belkyra® (Kybella®) 1.4 1.5 (0.1) (6.7)%
Plastic Surgery 44.5 38.0 6.5 17.1%
Breast Implants 44.1 37.6 6.5 17.3%
Earfold™ 0.4 0.4 - 0.0%
Regenerative Medicine 4.9 2.0 2.9 145.0%
Alloderm® 2.2 1.2 1.0 83.3%
Other Regenerative Medicine 2.7 0.8 1.9 n.m.
Body Contouring 9.2 - 9.2 n.a.
Coolsculpting® Systems & Add On Applicators 1.1 - 1.1 n.a.
Coolsculpting® Consumables 8.1 - 8.1 n.a.
Skin Care 3.8 2.2 1.6 72.7%
Botox® Therapeutics and Other 149.7 133.9 15.8 11.8%
Botox® Therapeutics 96.2 82.4 13.8 16.7%
Asacol®/Delzicol® 11.7 12.1 (0.4) (3.3)%
Constella® 5.6 4.9 0.7 14.3%
Other Products 36.2 34.5 1.7 4.9%
Other Revenues 12.1 15.8 (3.7) (23.4)%
Net revenues $ 864.0 $ 737.3 $ 126.7 17.2%

Cost of sales(1) 120.9 100.3 20.6 20.5%

Selling and marketing 245.7 209.5 36.2 17.3%
General and administrative 31.4 29.9 1.5 5.0%
Segment contribution $ 466.0 $ 397.6 $ 68.4 17.2%
Segment margin 53.9% 53.9% 0.0%
Segment gross margin(2) 86.0% 86.4% (0.4)%
(1) Excludes amortization and impairment of acquired intangibles including product rights.

(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues.
39
Table 12: Reconciliation of anticipated GAAP loss from continuing operations to non-GAAP
performance net income attributable to shareholders for the three months ending June 30, 2018
and twelve months ending December 31, 2018

Twelve months ending December 31,

Three months ending June 30, 2018 2018
(in millions, except per share information) LOW HIGH LOW HIGH
GAAP (loss) from continuing operations attributable to shareholders $ (233.0) $ (165.0) $ (905.0) $ (700.0)
Adjusted for:
Amortization 1,700.0 1,700.0 6,500.0 6,500.0
Acquisition, divestiture, licensing and other non-recurring charges 150.0 150.0 695.0 695.0
Accretion and fair-value adjustments to contingent 5.0 5.0 20.0 20.0
consideration sales and related costs
Impairment/asset - - 730.0 730.0
Non-recurring (gains) / losses - - - -
Non-acquisition restructurings, including Global Supply Chain initiatives 10.0 10.0 50.0 50.0
Legal settlements - - 10.0 10.0
Income taxes on items above and other discrete income tax adjustments (260.0) (260.0) (1,700.0) (1,700.0)
Non-GAAP performance net income attributable to shareholders 1,372.0 1,440.0 5,400.0 5,605.0

Diluted earnings per share

Diluted (loss) per share from continuing operations attributable to

$ (0.69) $ (0.49) $ (2.67) $ (2.06)
shareholders- GAAP

Non-GAAP performance diluted net income per share attributable to

shareholders $ 4.00 $ 4.20 $ 15.65 $ 16.25

Basic weighted average ordinary shares outstanding 339.0 339.0 339.0 339.0
Effect of dilutive securities:
Dilutive shares 4.0 4.0 6.0 6.0
Diluted weighted average ordinary shares outstanding 343.0 343.0 345.0 345.0

40
Table 13: Three months ended March 31, 2018 and 2017 Revenue Performance Drivers by product
ALLERGAN PLC
NET REVENUES TOP GLOBAL PRODUCTS
(Unaudited; in millions)

Three Months Ended March 31, 2018 Three Months Ended March 31, 2017 Movement
US Specialized US General US Specialized US General Total Change
Therapeutics Medicine International Corporate Total Therapeutics Medicine International Corporate Total Total Change Percentage

Botox® $ 572.5 $ - $ 244.8 $ - $ 817.3 $ 509.4 $ - $ 204.6 $ - $ 714.0 $ 103.3 14.5%

Juvederm Collection 122.8 - 146.1 - 268.9 119.8 - 122.2 - 242.0 26.9 11.1%
Linzess®/Constella® - 159.3 5.6 - 164.9 - 147.6 4.9 - 152.5 12.4 8.1%
Lumigan®/Ganfort® 66.8 - 100.4 - 167.2 74.3 - 85.9 - 160.2 7.0 4.4%
Bystolic® /Byvalson® - 132.8 0.5 - 133.3 - 139.8 0.6 - 140.4 (7.1) (5.1)%
Alphagan®/Combigan® 84.2 - 44.2 - 128.4 86.4 - 42.3 - 128.7 (0.3) (0.2)%
Eye Drops 46.2 - 68.8 - 115.0 47.8 - 65.3 - 113.1 1.9 1.7%
Lo Loestrin® - 114.6 - - 114.6 - 99.8 - - 99.8 14.8 14.8%
Breast Implants 60.7 - 44.1 - 104.8 54.3 - 37.6 - 91.9 12.9 14.0%
Viibryd®/Fetzima® - 71.7 1.5 - 73.2 - 72.5 0.4 - 72.9 0.3 0.4%
Alloderm 99.5 - 2.2 - 101.7 54.1 - 1.2 - 55.3 46.4 83.9%
Vraylar® - 84.4 - - 84.4 - 53.6 - - 53.6 30.8 57.5%
Coolsculpting Consumables 53.4 - 8.1 - 61.5 - - - - - 61.5 0.0%
Ozurdex ® 25.5 - 64.4 - 89.9 22.5 - 51.1 - 73.6 16.3 22.1%
Carafate ® /Sulcrate ® - 56.0 0.7 - 56.7 - 58.7 0.7 - 59.4 (2.7) (4.5)%
Zenpep® - 52.9 - - 52.9 - 46.5 - - 46.5 6.4 13.8%
Coolsculpting Systems & Add On Applicators 33.7 - 1.1 - 34.8 - - - - - 34.8 0.0%
Viberzi® - 35.9 0.1 - 36.0 - 31.5 - - 31.5 4.5 14.3%
Namzaric® - 33.4 - - 33.4 - 23.6 - - 23.6 9.8 41.5%
Teflaro® - 32.2 - - 32.2 - 30.6 - - 30.6 1.6 5.2%
Dalvance® - 11.9 - - 11.9 - 9.6 - - 9.6 2.3 24.0%
Avycaz® - 21.8 - - 21.8 - 11.3 - - 11.3 10.5 92.9%
Kybella® /Belkyra® 8.2 - 1.4 - 9.6 15.1 - 1.5 - 16.6 (7.0) (42.2)%
Other Regenerative Medicine 28.7 - 2.7 - 31.4 21.4 - 0.8 - 22.2 9.2 41.4%
Other Promoted Products 6.2 - 5.2 - 11.4 0.6 - 3.4 - 4.0 7.4 185.0%
Total Promoted Brands & Brands with Ongoing Exclusivity 1,208.4 806.9 741.9 - 2,757.2 1,005.7 725.1 622.5 - 2,353.3 403.9 17.2%

Restasis® 255.8 - 18.3 - 274.1 308.8 - 13.9 - 322.7 (48.6) (15.1)%

Namenda XR® - 40.5 - - 40.5 - 122.0 - - 122.0 (81.5) (66.8)%
Estrace® Cream - 6.4 - - 6.4 - 73.4 - - 73.4 (67.0) (91.3)%
Asacol®/Delzicol® - 38.2 11.7 - 49.9 - 57.6 12.1 - 69.7 (19.8) (28.4)%
Aczone® 16.0 - 0.1 - 16.1 40.6 - - - 40.6 (24.5) (60.3)%
Canasa®/Salofalk® - 38.6 4.2 - 42.8 - 38.3 4.4 - 42.7 0.1 0.2%
Rapaflo® 22.8 - 1.2 - 24.0 25.9 - 2.0 - 27.9 (3.9) (14.0)%
Minastrin® 24 - 5.2 - - 5.2 - 41.1 - - 41.1 (35.9) (87.3)%
Namenda® IR - 0.1 - - 0.1 - 0.1 - - 0.1 - 0.0%
Total Brands facing LOE Risk 294.6 129.0 35.5 - 459.1 375.3 332.5 32.4 - 740.2 (281.1) (38.0)%

Saphris® - 32.7 - - 32.7 - 37.3 - - 37.3 (4.6) (12.3)%

Tazorac® 9.4 - 0.2 - 9.6 23.4 - 0.2 - 23.6 (14.0) (59.3)%
SkinMedica® 18.1 - 1.6 - 19.7 28.0 - - - 28.0 (8.3) (29.6)%
Latisse® 13.8 - 2.2 - 16.0 13.6 - 1.9 - 15.5 0.5 3.2%
Liletta® - 8.1 - - 8.1 - 7.2 - - 7.2 0.9 12.5%
Armour Thyroid - 48.2 - - 48.2 - 37.3 - - 37.3 10.9 29.2%
Savella® - 19.9 - - 19.9 - 24.3 - - 24.3 (4.4) (18.1)%
Lexapro® - 14.7 - - 14.7 - 13.4 - - 13.4 1.3 9.7%
Enablex® - 0.8 - - 0.8 - 0.9 - - 0.9 (0.1) (11.1)%
Other Products Revenues 34.3 163.4 82.6 5.8 286.1 36.0 167.8 80.3 7.8 291.9 (5.8) (2.0)%
Total Other 75.6 287.8 86.6 5.8 455.8 101.0 288.2 82.4 7.8 479.4 (23.6) (4.9)%

Total Net Revenues $ 1,578.6 $ 1,223.7 $ 864.0 $ 5.8 3,672.1 $ 1,482.0 $ 1,345.8 $ 737.3 $ 7.8 3,572.9 $ 99.2 2.8%

41